The company is currently outrageously undervalued. It's really absurd. Not even a baboon would be caught selling down here. It will be interesting to see when big money final decides to start pushing this up. $40M market cap for a company with a Phase III NASH asset with greatest safety profile of any NASH drug in development? You have to be kidding. I am happy to wait and add some when I can at these levels.
Add to My Watchlist
What is My Watchlist?
